Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data

SYDNEY, Australia, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product rhDNase(1). The improvement in lung function after three months on Bronchitol reflects that seen in a previous study following two weeks of treatment.

The study was an independent investigator initiated study conducted in the United Kingdom in 20 children with a mean age of 13 years. Those children enrolled in the trial completed three months treatment with each of three different therapies - Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial measured changes in lung function, airway inflammation, infections, and quality of life.

At the end of the treatment period, lung function as determined by measuring FEV1 (the amount of air that can be forcibly exhaled in 1 second) improved by:

-- 7% while the subjects were on Bronchitol

-- 7% while subjects were on rhDNase and

-- 2% while subjects were on both agents together.

The study had insufficient numbers to reach a definitive statistical conclusion.

People affected by cystic fibrosis typically experience a decline in lung function of 1-2% every year of their life, as measured by FEV1.

Pharmaxis Chief Executive Officer Alan Robertson said: 'While not on the regulatory approval path, this is the first time we have had an opportunity to measure the performance of Bronchitol following 3 months continuous treatment and it bodes well for the pivotal 6 month Phase 3 trial that is currently in progress. Although the two agents worked less well when taken together, the patient numbers are low and a previous study has shown a benefit to using both therapies together.'

Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. rhDNase is designed to improve mucus viscosity. Additional data from this trial will be presented by the independent investigator at a forthcoming scientific congress. A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis, is currently enrolling subjects.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.
To find out more about Pharmaxis, go to

1: rhDNase is marketed as Pulmozyme, which is a trade mark of Genentech


SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email

Released through:

Australia: Virginia Nicholls, phone +61 417 610 824 or email

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email

About the Trial

The following information is provided in accord with the ASX and AusBiotech Code of Best Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.

Name of Trial DPM - CF-203 (A phase II study with


Blinding Status Open label

Placebo Controlled No

Treatment Method

Route Inhalation

Frequency Twice per day

Dose levels 400 mg

Number of Subjects 20 evaluable

Subject Selection Criteria Subjects with a known diagnosis of cystic

fibrosis, FEV1 < 70% of predicted, of either

gender, aged between 8 and 19 years of age and

currently receiving rhDNase or eligible to

receive rhDNase.

Primary End Points To compare and contrast the effect on FEV1 of:

1: Bronchitol to rhDNase

2: Bronchitol + rhDNase to rhDNase

Secondary End Points To assess whether:

1: the effects of Bronchitol are additive to


2: Bronchitol reduces the bacterial load in

the lung

3: the effects of Bronchitol are beneficial

to quality of life

Trial Location United Kingdom

Commercial partners Pharmaxis Ltd

Sponsor Investigator initiated, Pharmaxis supported

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
(Date:11/24/2015)... ... 2015 , ... In harsh industrial processes, the safety of ... can represent a weak spot where leaking process media is a possible hazard. ... , which are designed to tolerate extreme process conditions. They combine rugged design ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):